{"url":"https://lda.senate.gov/api/v1/filings/75010f1a-bebf-4c30-b71f-eefac384a8a7/","filing_uuid":"75010f1a-bebf-4c30-b71f-eefac384a8a7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2016,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/75010f1a-bebf-4c30-b71f-eefac384a8a7/print/","filing_document_content_type":"text/html","income":null,"expenses":"280000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Sara Froelich","dt_posted":"2016-07-20T23:45:37.913000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1455 Pennsylvania Ave., NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16054,"url":"https://lda.senate.gov/api/v1/registrants/16054/","house_registrant_id":30257,"name":"GENZYME CORPORATION","description":null,"address_1":"1455 Pennsylvania Ave., NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARA FROELICH","contact_telephone":"+1 202-585-3031","dt_updated":"2022-04-06T16:04:30.357016-04:00"},"client":{"id":121531,"url":"https://lda.senate.gov/api/v1/clients/121531/","client_id":12,"name":"GENZYME CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade Promotion Authority legislation and other trade issues, including the Trans-Pacific Partnership (TPP)\nProtection and promotion of 12 years exclusivity for biosimilars \nProtection and Promotion of Orphan Drug Act market exclusivity","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) \nExcise tax for drugs and biologics\nIssues and policies related to Orphan Drug Tax Credit\nImplementation of American Taxpayer Relief Act of 2012\nIssues and policies related to tax reform\nH.R. 880, American Research and Competitiveness Act of 2015\nS. 537, Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2015(COMPETE Act)\nCorporate tax inversions issues\nLegislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015\nH.R. 3618 and S. 1906, Orphan Drug Fairness Act\nProtecting Americans From Tax Hikes Act of 2015 (PATH)","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Patent settlement legislation, including HR 9, Innovation Act of 2015, S. 632, STRONG Patents Act of 2015, and S.1137, PATENT Act\nS.2019, Preserve Access to Affordable Generics Act\nS. 3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) \n340B issues and legislative reform proposals\nIssues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015\nHealth technology assessment of orphan drugs\nSequestration of FDA user fees\nH.R. 1376, Patient Choice Act of 2015\nH.R. 790, Compassionate Freedom of Choice Act of 2015\nH.R. 1600, Patients' Access to Treatments Act of 2015\n21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act \nH.R. 909, Andrea Sloan CURE Act\nS. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015\nImplementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144)\nRegulation of innovative biological products for neurodegenerative diseases\nIssues and policies related to implementation of Orphan Drug Act and orphan drug development\nS. 320, Medical Innovation Act\nH.R. 744, Medical Innovation Act\nS. 2615, Increasing Competition in Pharmaceuticals Act  \nH.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015\nS. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015\nH.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015\nH.R. 1531 and S.1878, Advancing Hope Act of 2015\nImplementation of newborn screening programs\nIssues and policies related to biosimilars exclusivity period\nIssues and policies related to biosimilars FDA guidance\nIssues and policies related to FDA oversight and management\nIssues and policies related to expanded access programs\nIssues and policies related to patient involvement with FDA decision making\nS. 289 and H.R. 2104, American Cures Act\nLegislation pertaining to FDA priority review vouchers, generally\nLegislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015\nH.R. 3618 and S. 1906, Orphan Drug Fairness Act\nIssues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015\nDrug shortage issues\nIssues related to health care transparency  \nS. 2055, Medical Countermeasure Innovation Act of 2016\nH.R. 3299, Strengthening Public Health Emergency Response Act \nS. 2700, FDA and NIH Workforce Authorities Modernization Act\nS. 2713, Advancing Precision Medicine Act of 2016 \nS. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act\nS. 2742, Promoting Biomedical Research and Public Health for Patients Act\nS. 3239, H.R. 5858, The RACE for Children Act\nS. 2689, The REGROW Act","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Part D drug coverage and patient access issues and policy\nESRD bundling and drug reimbursement issues\nHCPCS coding and reimbursement decisions\nImplementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) \nLeast costly alternative (LCA) policy\nChanges re: Medicare Part B and Average Sales Price\nMedicare secondary payor for ESRD services\nExtension of rebates on Medicare Part D drugs\nPerformance measures for bone and  mineral metabolism for ESRD program\nImplementation of American Taxpayer Relief Act of 2012\nH.R. 1416, Cancer Patient Protection Act of 2015\n21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act\nS. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes\nH.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes\nMedicaid drug rebate, drug coverage and patient access to therapies issues and policy\nS. 31, Medicare Prescription Drug Price Negotiation Act of 2015\nH.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015\nS. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015\nS. 648, Medicare Formulary Improvement Act of 2015\nH.R. 2, Medicare Access and CHIP Reauthorization Act of 2015\nH.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015\nH.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Funding for FDA and NIH\nIssues and policies related to FY 2017 Appropriations and all applicable amendments\nH.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015\nH.R.3762, To provide for reconciliation pursuant to section 2002 of the concurrent resolution on the budget for FY 2016\nIssues and policies related to H.Con.Res. 125, House FY 2017 budget resolution and all applicable amendments","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Food and Drug Administration Safety and Innovation Act (FDASIA) implementation \nIssues and policies related to biosimilars exclusivity period\nBiosimilars FDA guidance\nImplementation of Drug Quality and Security Act\nImplementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) \nIssues and policies related to FDA oversight and management\nIssues and policies related to expanded access programs\nIssues and policies related to patient involvement with FDA decision making\nS.2912, Trickett Wendler Right to Try Act of 2016\nH.R. 3012, Right to Try Act of 2015","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}